

Anti-HLA DMB/HLA-DMB Antibody Picoband®

Catalog Number: PA1788

About HLA-DMB

HLA-DMB (major histocompatibility complex, class II, DM beta), also known as D6S221E, RING7, HLA-DM histocompatibility type, beta chain, HLADMB or RING7, is a protein that in humans is encoded by the HLA-DMB gene. The HLA-DMB gene is mapped on 6p21.32. HLA-DMB belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DMA) and a beta (DMB) chain, both anchored in the membrane. It is located in intracellular vesicles. DM plays a central role in the peptide loading of MHC class II molecules by helping to release the CLIP (class II-associated invariant chain peptide) molecule from the peptide binding site. Class II molecules are expressed in antigen presenting cells. The beta chain is approximately 26-28 kDa and its gene contains 6 exons. HLA-DMA and -DMB appear to encode subunits of a functional heterodimer that is critical in the pathway of class II antigen presentation.

Overview

Product Name	Anti-HLA DMB/HLA-DMB Antibody Picoband®
Reactive Species	Human
Description	Boster Bio Anti-HLA DMB/HLA-DMB Antibody catalog # PA1788. Tested in IHC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Application	IHC, WB
Clonality	Polyclonal
Formulation	Each vial contains antibody formulated with stabilizing components, 0.9mg NaCl, 0.2mg Na ₂ HPO ₄ , 0.05mg Thimerosal, 0.05mg NaN ₃ . *This antibody is supplied in a stabilized formulation. Compatibility with conjugation reactions depends on the chemistry of the conjugation method used. For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.
Storage Instructions	Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
Host	Rabbit
Uniprot ID	P28068

Technical Details


Immunogen	A synthetic peptide corresponding to a sequence in the middle region of human HLA DMB.
Recommended Detection Systems	Boster recommends Enhanced Chemiluminescent Kit with anti-Rabbit IgG (EK1002) for Western blot, and HRP Conjugated anti-Rabbit IgG Super Vision Assay Kit (SV0002-1) for IHC(P).

Cross Reactivity	No cross-reactivity with other proteins
Isotype	Rabbit IgG
Form	Lyophilized
Concentration	Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml.
Purification	Immunogen affinity purified.
Suggested Dilutions	Immunohistochemistry (Paraffin-embedded Section), 0.5-1ug/ml, Human Western blot, 0.1-0.5ug/ml, Human


Anti-HLA DMB/HLA-DMB Antibody Picoband® (PA1788) Images



Anti-HLA DMB antibody, PA1788, Western blotting All lanes:
Anti HLA DMB (PA1788) at 0.5ug/ml Lane 1: JURKAT Whole Cell Lysate at 40ug Lane 2: JURKAT Whole Cell Lysate at 40ug Lane 3: RAJI Whole Cell Lysate at 40ug Lane 4: HUT Whole Cell Lysate at 40ug Predicted bind size: 29KD
Observed bind size: 29KD



Anti-HLA DMB antibody, PA1788, IHC(P)IHC(P): Human Mammary Cancer Tissue



miR-411-5p activate p38MAPK pathway by targeting SPRY4-induced terminal differentiation of RMS. (a) Western blot analysis of p38MAPK activation (P-p38MAPK: p-38) in RMS cells treated with HA-tagged MKK6EE protein-expressing pcDNA3, SPRY4 siRNA, or both. (b) Western blot analysis of p38MAPK activation (P-p38MAPK:p-38) in RMS cells treated with miR-411-5p-M, miR-411-5p-I, and MKK6EE protein-expressing pcDNA3 plus miR-411-5p-M. (c) Terminal differentiation of RD cells after treatment with SPRY4 siRNA or miR-411-5p-M for 6 and 48 h. Cells stained with apoptosis marker (caspase-3); cell cycle was analyzed using propidium iodide (PI) and showed changed morphology (MHC and myosin) after activation of p38MAPK caused by SPRY4 siRNA or miR-411-5p-M. Scale bars: panel (Caspase-3)=100 u m, panel (MHC and Myosin)=20 u m. (d) Quantitation of terminal differentiation of RD cells after treatment with SPRY4 siRNA or miR-411-5p-M for 6 and 48 h. (e) Graphical representation of cell cycle phase proportions in RD cells after treatment with miR-411-5p-M for 6 and 48 h. (f) Proliferation of RD cells was evaluated by [3 H] thymidine incorporation assay after treatment with SPRY4 siRNA or miR-411-5p-M for 4 days. The amount of [3 H] thymidine incorporated was measured with a liquid scintillation counter. The OD at 557 nm was determined using a microplate reader. (g) Western blot analysis of cleaved caspase-3 in RMS cells treated with SPRY4 siRNA or miR-411-5p-M for 24 and 72 h. Each assay (a - g) was conducted at least three times independently. Error bars indicate S.D. * P

Submit a product review to Biocompare.com

Submit a review of this product to Biocompare.com to receive a \$20 Amazon.com giftcard! Your reviews help your fellow scientists make the right decisions. Thank you for your contribution.



Anti-HLA DMB/HLA-DMB Antibody

For Research Use Only. Not for use in diagnostic procedures.